Over the last several months, there have been reports that the FDA was considering new warnings for neuronal stabilizing agents (antiseizure medications) that are used not only to treat seizure disorders, but also depression, bipolar disorder, Migraine disease, and other conditions.

After analyzing reports of suicidality (suicidal behavior or ideation [thoughts]), the FDA is requiring all manufacturers of medications in this class to include a new warning on their labeing and develop a medication guide to be given topatients for whom these medications are prescribed to alert them of the risks of suicidality.

An article I wrote for our MyMigraineConnection has more information on this that applies to all uses of these medications, not just Migraine prevention.

Continue reading Neuronal Stabilizing Agents To Carry New Warning.